# US 2024/0199752 A1 · Treatment of ophthalmic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199752 A1
- Document ID: US20240199752A1
- Status: Published application
- Kind: A1
- Application number: 18/556,627
- Filed: 2022-04-22
- Published: 2024-06-20
- Earliest claimed: 2021-04-23
- Assignees: AmMax Bio, Inc.
- Applicants: AmMax Bio, Inc.
- Inventors: Kirk William JOHNSON; Laman ALANI
- Web page: https://patentgrep.com/patent/US20240199752A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/31: multispecific
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are pharmaceutical compositions and related methods for treating ophthalmic diseases. The method entails administering to the patient an effective amount of a CSF1R inhibitor, such as an anti-CSF1R antibody. The methods are effective in reducing vascular hyperpermeability, neovascularization and fibrosis such as macular fibrosis. Combination therapies that also include a VEGF inhibitor are also provided. Preferably, the administration is via intravitreal injection.

## Claims

### Claim 1

A method for treating an ophthalmic disease in a human patient in need thereof, comprising administering to the patient an effective amount of a CSF1R inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ophthalmic disease is characterized with vascular hyperpermeability.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ophthalmic disease is characterized with neovascularization.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ophthalmic disease is characterized with fibrosis, which is optionally subretinal macular fibrosis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ophthalmic disease is selected from the group consisting of age-related macular degeneration (AMD), anterior segment neovascularization, central retinal vein occlusion (CRVO), choroidal neovascularization (CNV), corneal neovascularization, diabetic macular edema (DME), diabetic retinopathy, dry eye syndrome (DES), glaucoma, noninfectious uveitis (NIU), polypoidal choroidal vasculopathy, posterior segment neovascularization, proliferative diabetic retinopathy (PDR), proliferative vitreoretinopathy, retinal edema, retinal vein occlusion (RVO), retinopathy of prematurity (ROP), sequela associated with retinal ischemia, and uveitis.

### Claim 6 (depends on 4)

The method of claim 4, wherein the ophthalmic disease is AMD, which is optionally exudative AMD (wetAMD or neovascular AMD).

### Claim 7 (depends on 4)

The method of claim 4, wherein the ophthalmic disease is PDR.

### Claim 8 (depends on 4)

The method of claim 4, wherein the ophthalmic disease is DME.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering to the patient a VEGF inhibitor, which is optionally formulated together with the CSF1R inhibitor, or administered separately from the CSF1R inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the VEGF inhibitor is an anti-VEGF antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the CSF1R inhibitor is an anti-CSF1R antibody.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anti-CSF1R antibody and the anti-VEGF antibody are provided as a bispecific antibody having specificity to both CSF1R and VEGF.

### Claim 13 (depends on 9)

The method of claim 9, wherein the VEGF inhibitor is a VEGF-trap.

### Claim 14 (depends on 13)

The method of claim 13, wherein the VEGF-trap and the anti-CSF1R antibody are provided as bifunctional molecule.

### Claim 15 (depends on 11)

The method of claim 11, wherein the anti-CSF1R antibody is selected from the group consisting of emactuzumab, cabiralizumab, IMC-CS4, AM001, axatilimab, and antigen-binding fragments thereof.

### Claim 16 (depends on 11)

The method of claim 11, wherein the anti-CSF1R antibody is AM001 or an antigen-binding fragment thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the administration results in reduction or prevention of ocular fibrosis.

### Claim 18 (depends on 1)

The method of claim 1, wherein the administration is intravitreal injection.

### Claim 19 (depends on 18)

The method of claim 18, wherein the administration is once every one, two, three, four, five, or six months.
